文献速递糖尿病

目标范围内时间作为糖尿病临床试验结局指标的验证

Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.
PubMed 文献 · Diabetes Care · 2018-10-23

该研究利用DCCT数据集评估TIR(70-180 mg/dL)与视网膜病变进展及微量白蛋白尿发生的关联,以验证TIR作为临床试验结局指标。1440名参与者平均TIR为41±16%,TIR每降低10个百分点,视网膜病变进展风险增加64%(95%CI 51-78),微量白蛋白尿风险增加40%(95%CI 25-56),均P<0.001。结论认为TIR与微血管并发症风险强烈相关,应作为临床试验可接受的终点。

要点

  • TIR每降低10个百分点,视网膜病变进展风险增加64%。
  • TIR每降低10个百分点,微量白蛋白尿风险增加40%。
  • TIR与微血管并发症风险强烈相关,可作为临床试验终点。

核心结论

  • TIR与微血管并发症风险强烈相关,应作为临床试验可接受的终点。
  • HbA1c仍是重要结局指标,但TIR等指标(尤其CGM测量时)在许多研究中增加价值。

研究设计与样本

  • 基于DCCT数据集的事后分析,纳入1440名参与者。
  • 每3个月进行1天七点指尖血糖检测(餐前、餐后90分钟及睡前),每6个月评估视网膜病变,每12个月评估微量白蛋白尿。
  • 采用比例风险模型评估TIR等血糖指标与微血管并发症发生的关联。

主要发现

  • 七点血糖谱平均TIR为41±16%。
  • TIR每降低10个百分点,视网膜病变进展风险增加64%(95%CI 51-78,P<0.001)。
  • TIR每降低10个百分点,微量白蛋白尿风险增加40%(95%CI 25-56,P<0.001)。
  • 平均血糖和高血糖指标的结果与TIR相似。

临床怎么用

  • 在内分泌科临床试验中,可将TIR作为微血管并发症风险的替代终点。
  • 解读TIR时需注意其与视网膜病变和微量白蛋白尿风险的量化关联。

局限性

  • TIR基于每3个月1天的七点指尖血糖数据计算,非持续葡萄糖监测。
  • 研究为基于DCCT数据集的回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study evaluated the association of time in range (TIR) of 70-180 mg/dL (3.9-10 mmol/L) with the development or progression of retinopathy and development of microalbuminuria using the Diabetes Control and Complications Trial (DCCT) data set in order to validate the use of TIR as an outcome measure for clinical trials. RESEARCH DESIGN AND METHODS: In the DCCT, blood glucose concentrations were measured at a central laboratory from seven fingerstick samples (seven-point testing: pre- and 90-min postmeals and at bedtime) collected during 1 day every 3 months. Retinopathy progression was assessed every 6 months and urinary microalbuminuria development every 12 months. Proportional hazards models were used to assess the association of TIR and other glycemic metrics, computed from the seven-point fingerstick data, with the rate of development of microvascular complications. RESULTS: Mean TIR of seven-point profiles for the 1,440 participants was 41 ± 16%. The hazard rate of development of retinopathy progression was increased by 64% (95% CI 51-78), and development of the microalbuminuria outcome was increased by 40% (95% CI 25-56), for each 10 percentage points lower TIR (P < 0.001 for each). Results were similar for mean glucose and hyperglycemia metrics. CONCLUSIONS: Based on these results, a compelling case can be made that TIR is strongly associated with the risk of microvascular complications and should be an acceptable end point for clinical trials. Although hemoglobin A1c remains a valuable outcome metric in clinical trials, TIR and other glycemic metrics-especially when measured with continuous glucose monitoring-add value as outcome measures in many studies.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2018. PMID: 30352896. doi:10.2337/dc18-1444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。